# A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.

> **NCT00495118** · PHASE3 · COMPLETED · sponsor: **Janssen, LP** · enrollment: 314 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00495118
- **Lead sponsor:** Janssen, LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495118, "A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00495118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*